ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Taipei City, TWN:

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

evaluate the efficacy and safety of Acalabrutinib versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia...

Active, not recruiting
Untreated Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Taipei, Taiwan and 46 other locations

(bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: tre...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Acalabrutinib

Phase 3

AstraZeneca
AstraZeneca

Taipei, Taiwan and 108 other locations

in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) either in presence of 17p de...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Small Lymphocytic Lymphoma (SLL)
Drug: Venetoclax

Phase 2

AbbVie
AbbVie

Taipei City, Taipei, Taiwan and 30 other locations

with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Taipei City, Taipei, Taiwan and 108 other locations

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of bleximenib in phase 1 (Part 1 \[Dose Escalation\] and to det...

Enrolling
Acute Leukemias
Acute Lymphoblastic Leukemia
Drug: Bleximenib

Phase 1, Phase 2

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Taipei, Taiwan and 95 other locations

Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Taipei City, Taiwan and 171 other locations

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Taipei City, Taipei, Taiwan and 160 other locations

safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia...

Enrolling
LGLL - Large Granular Lymphocytic Leukemia
Aggressive NK Cell Leukemia
Drug: DR-01

Phase 1, Phase 2

Dren Bio

Taipei, Taiwan and 33 other locations

and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia...

Enrolling
Leukemia, Myeloid, Acute
Drug: Venetoclax (VEN)
Drug: Azacitidine (AZA)

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Taipei City, Taiwan and 12 other locations

with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when g...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Cancer
Drug: Venetoclax
Drug: Azacitidine

Phase 3

AbbVie
AbbVie

Taipei, Taiwan and 164 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems